AU2018237139A1 - Modified oligonucleotides and therapeutic uses thereof - Google Patents

Modified oligonucleotides and therapeutic uses thereof Download PDF

Info

Publication number
AU2018237139A1
AU2018237139A1 AU2018237139A AU2018237139A AU2018237139A1 AU 2018237139 A1 AU2018237139 A1 AU 2018237139A1 AU 2018237139 A AU2018237139 A AU 2018237139A AU 2018237139 A AU2018237139 A AU 2018237139A AU 2018237139 A1 AU2018237139 A1 AU 2018237139A1
Authority
AU
Australia
Prior art keywords
compound
moiety
pharmaceutical composition
protein
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2018237139A
Other languages
English (en)
Inventor
Paul A. Bertin
Cassandra E. CALLMANN
Nathan C. Gianneschi
Alexander Roloff
Matthew P. THOMPSON
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vybyl Holdings Inc
University of California, San Diego
Original Assignee
Vybyl Holdings Inc
University of California Berkeley
University of California, San Diego
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vybyl Holdings Inc, University of California Berkeley, University of California, San Diego filed Critical Vybyl Holdings Inc
Publication of AU2018237139A1 publication Critical patent/AU2018237139A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2018237139A 2017-03-22 2018-03-21 Modified oligonucleotides and therapeutic uses thereof Abandoned AU2018237139A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762475185P 2017-03-22 2017-03-22
US62/475,185 2017-03-22
PCT/US2018/023578 WO2018175592A1 (en) 2017-03-22 2018-03-21 Modified oligonucleotides and therapeutic uses thereof

Publications (1)

Publication Number Publication Date
AU2018237139A1 true AU2018237139A1 (en) 2019-10-17

Family

ID=63586170

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018237139A Abandoned AU2018237139A1 (en) 2017-03-22 2018-03-21 Modified oligonucleotides and therapeutic uses thereof

Country Status (9)

Country Link
US (1) US20200046846A1 (cg-RX-API-DMAC7.html)
EP (1) EP3600439A4 (cg-RX-API-DMAC7.html)
JP (1) JP2020514383A (cg-RX-API-DMAC7.html)
KR (1) KR20190123351A (cg-RX-API-DMAC7.html)
CN (1) CN110636865A (cg-RX-API-DMAC7.html)
AU (1) AU2018237139A1 (cg-RX-API-DMAC7.html)
CA (1) CA3057292A1 (cg-RX-API-DMAC7.html)
SG (1) SG11201908771YA (cg-RX-API-DMAC7.html)
WO (1) WO2018175592A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4213883A1 (en) * 2020-09-16 2023-07-26 Astrazeneca AB Oligonucleotides conjugated to fatty acids
EP4398939A1 (en) * 2021-09-10 2024-07-17 Guardian Therapeutics, LLC Fatty acid conjugates of nucleic acids
EP4755898A1 (en) * 2023-08-02 2026-06-10 Nitto Denko Corporation Method for producing oligonucleotide

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2216844A1 (en) * 1995-03-31 1996-10-03 Drug Delivery System Institute, Ltd. Amidite derivatives and oligonucleotide derivatives
US8969543B2 (en) * 2003-04-03 2015-03-03 Bioneer Corporation SiRNA-hydrophilic polymer conjugates for intracellular delivery of siRNA and method thereof
US20090306178A1 (en) * 2006-03-27 2009-12-10 Balkrishen Bhat Conjugated double strand compositions for use in gene modulation
KR101224828B1 (ko) * 2009-05-14 2013-01-22 (주)바이오니아 siRNA 접합체 및 그 제조방법
GB0910723D0 (en) * 2009-06-22 2009-08-05 Sylentis Sau Novel drugs for inhibition of gene expression
WO2012165616A1 (ja) * 2011-06-03 2012-12-06 国立大学法人北海道大学 オリゴヌクレオチド誘導体、オリゴヌクレオチド誘導体を含む治療用医薬組成物及び診断用医薬組成物、並びにmiRNA機能抑制用オリゴヌクレオチド誘導体
PL2796150T3 (pl) * 2011-12-15 2021-08-30 Bioneer Corporation Nowe koniugaty oligonukleotydowe i ich zastosowanie
WO2015006740A2 (en) * 2013-07-11 2015-01-15 Alnylam Pharmaceuticals, Inc. Oligonucleotide-ligand conjugates and process for their preparation
WO2015038938A1 (en) * 2013-09-13 2015-03-19 The California Institute For Biomedical Research Modified therapeutic agents and compositions thereof
US10039809B2 (en) * 2013-12-18 2018-08-07 The California Institute For Biomedical Research Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
US9803201B2 (en) * 2015-03-17 2017-10-31 Arrowhead Pharmaceuticals, Inc. Disulfide-containing alkyne linking agents
MA41794A (fr) * 2015-03-18 2018-01-23 The California Institute For Biomedical Res Agents thérapeutiques modifiés et compositions associées
WO2017030973A1 (en) * 2015-08-14 2017-02-23 University Of Massachusetts Bioactive conjugates for oligonucleotide delivery
MY193776A (en) * 2015-09-22 2022-10-27 Univ California Modified cytotoxins and their therapeutics use

Also Published As

Publication number Publication date
EP3600439A1 (en) 2020-02-05
CN110636865A (zh) 2019-12-31
US20200046846A1 (en) 2020-02-13
SG11201908771YA (en) 2019-10-30
JP2020514383A (ja) 2020-05-21
KR20190123351A (ko) 2019-10-31
CA3057292A1 (en) 2018-09-27
WO2018175592A1 (en) 2018-09-27
EP3600439A4 (en) 2021-01-13

Similar Documents

Publication Publication Date Title
TWI882566B (zh) 一種含有核糖環或其衍生結構的GalNAc化合物及其寡核苷酸綴合物
AU2007296054B2 (en) Hindered ester-based biodegradable linkers for oligonucleotide delivery
EP3992291B1 (en) Novel compound and application thereof
US9968686B2 (en) Antisense oligonucleotides with improved pharmacokinetic properties
CN117858948A (zh) 新的治疗剂递送部分及其用途
TW202203972A (zh) 治療性化合物之標靶性配體
US20250223594A1 (en) Modified double-stranded oligonucleotide molecule, modified double-stranded oligonucleotide conjugate, and use thereof
TW201540724A (zh) 反義核酸
Homma et al. Synthesis and optimization of hyaluronic acid–methotrexate conjugates to maximize benefit in the treatment of osteoarthritis
TW202227135A (zh) 用於遞送治療劑之脂質結合物
ES3030929T3 (en) Arnatar compounds and methods for enhanced cellular uptake
CA3057292A1 (en) Modified oligonucleotides and therapeutic uses thereof
CN116133691A (zh) 与脂肪酸缀合的寡核苷酸
CN101870719B (zh) 一种同时具有二硫化学键和甾体骨架结构的有机功能化合物、制备方法和用途
CN104185478B (zh) 用于靶向递送至表达lfa-1的细胞的整联蛋白拮抗剂缀合物
EP2806898B1 (en) Integrin antagonist conjugates for targeted delivery to cells expressing vla-4
CN120192244A (zh) 可电离脂质化合物及其制备方法和应用
WO2025255972A1 (zh) 用于靶向递送寡核苷酸药物的化合物、缀合物及其应用
CN103788165B (zh) 阿糖胞苷胆酸结合物及其制备方法和用途
US20210137957A1 (en) Modified anthracycline compounds and their therapeutic use
CN104271772A (zh) 点击核酸
US20200048198A1 (en) Modified histone deacetylase inhibitors and uses thereof
WO2026023273A1 (ja) リガンド-核酸コンジュゲート体およびそれを用いた医薬組成物
WO2025261376A1 (zh) 肝外递送配体及其缀合物
CN121517358A (zh) Cb1配体化合物及其缀合物

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period